Butterfly Network (BFLY) Q2 2026: Embedded Revenue Soars 439% as Platform Flywheel Accelerates
Butterfly Network’s Q2 marked a decisive inflection as embedded ultrasound revenue surged, driving record profitability and a guidance raise. The company’s multi-engine model—core POCUS, embedded, and home care—now shows reinforcing momentum, with the platform’s scalability and AI leverage attracting new partners and market opportunities. Execution on next-gen product launches and commercial transitions will determine the durability of these gains into 2027.
Summary
- Embedded Platform Momentum: Butterfly’s chip-based ultrasound partnerships are compounding, fueling new revenue streams and industry attention.
- Core and AI Ecosystem Expansion: Medical education, Compass AI, and Garden AI launches deepen workflow integration and recurring software leverage.
- Commercialization Pipeline Building: Home care and next-gen probes set up large new addressable markets, but execution risk remains pivotal.
Business Overview
Butterfly Network develops and commercializes semiconductor-based ultrasound imaging solutions, aiming to democratize medical imaging through handheld probes, embedded chips, and cloud-based AI software. The business operates three primary growth engines: POCUS (Point-of-Care Ultrasound), its core handheld and software platform; Embedded, which licenses and sells chip technology to device partners; and Home and Community Care, a new initiative enabling remote diagnostics in skilled nursing settings. Revenue streams span hardware sales, SaaS, licensing, development services, and per-scan fees.
Performance Analysis
Butterfly delivered record quarterly revenue, gross margin, and adjusted EBITDA, with total revenue climbing 39% year-over-year to $32.6 million. The standout driver was Embedded, which posted a 439% YoY surge to $10.8 million, propelled by the MidJourney partnership and new agreements in neurotechnology and women’s health wearables. Core POCUS revenue grew modestly, up 2% YoY to $21.9 million, supported by U.S. health systems, medical school contracts (notably VCOM), and expanding Compass AI adoption. International sales dipped 14% due to tough comps and order timing, but management expects a rebound in Q3, especially with Brazil’s regulatory greenlight.
Gross margin reached a record 71%, up 7.7 points YoY, reflecting the higher-margin mix from embedded. Adjusted EBITDA loss narrowed sharply, down 78% YoY, as Butterfly reallocated resources toward higher-ROI growth levers and maintained financial discipline. Unit sales rose 23%, though average selling price fell 12%, reflecting strategic discounting to expand medical education penetration and clear legacy inventory ahead of next-gen launches.
- Embedded Revenue Scale: Embedded now comprises a third of revenue, with recurring license, NRE, and chip sales layering atop core probe sales.
- Medical Education Penetration: VCOM partnership signals a shift to one-to-one device deployment and longitudinal tracking, with a $10 million four-year contract.
- AI Ecosystem Leverage: Compass AI and Garden partner launches are converting software into a recurring revenue and stickiness driver.
Cash burn increased to $13.3 million in the quarter, but the cash balance remains robust at $125 million, positioning Butterfly to fund expansion and R&D into 2027 product cycles.
Executive Commentary
"Our vision for a new category of chip-based ultrasound is unfolding right before our eyes... Butterfly's embedded actually amplifies Butterfly's core mission of democratizing imaging by partnering with companies who share that same vision."
Joseph DeVivo, Chairman and Chief Executive Officer
"Record revenue attainment above the high end of consensus and above the top end of our guidance. The highest gross margin for Butterfly in its history. Adjusted EBITDA that was above consensus and our guidance range, with improvement driven by our revenue performance, higher gross margin, and continued financial discipline."
John Doherty, Chief Financial Officer
Strategic Positioning
1. Embedded Platform Scale and Visibility
Butterfly Embedded, the company’s chip and licensing business, is rapidly scaling. With 11 signed partners spanning wearables, neurotech, and whole-body scanning, embedded revenue is becoming both recurring and diversified. The MidJourney deal alone is a $74 million contract, but management emphasized that new partners and milestone-driven commercialization can drive further upside, with the model built for high scalability and limited incremental cost per partner.
2. Core POCUS and Medical Education Expansion
POCUS, Butterfly’s core handheld probe and software business, is leveraging strategic partnerships with medical schools like VCOM to drive device proliferation and workflow integration. The VCOM deal, with subsidized pricing and a four-year runway, is a template for broadening the addressable market and depleting legacy inventory. Compass AI and cloud-based image storage create data network effects and recurring software revenue.
3. AI Ecosystem and Garden Commercialization
Garden, Butterfly’s developer and AI partner platform, is transitioning from ecosystem to commercial platform. Three partner AI tools are set to launch by year-end, with direct integration into Butterfly’s cloud and clinical workflows. This positions Butterfly as a central hub for AI-driven imaging applications, increasing user stickiness and broadening use cases.
4. Home and Community Care Commercial Launch
Home and Community Care, targeting skilled nursing facilities, is moving from pilot to commercial in Q4. The model charges per managed population and per scan, with the goal of reducing costly hospital readmissions. Management sees this as a potentially massive market, with scalability limited more by execution than by training or infrastructure.
5. Next-Gen Product and Cart Market Entry
The upcoming P5.1 chip and IQ Station are positioned to leapfrog current handheld and cart-based ultrasound offerings. Management claims image quality will surpass current market leaders, setting up for a 2027 launch that targets a $1.6 to $2 billion cart market. If successful, this could be a major share capture moment for Butterfly.
Key Considerations
This quarter marks a structural shift in Butterfly’s growth narrative, as embedded and AI-driven software revenue now reinforce core device sales. The company’s ability to standardize and scale the embedded platform, while executing on next-gen product launches and commercial transitions, will define its long-term trajectory.
Key Considerations:
- Embedded Revenue Cadence: Management expects $7-8 million per quarter from embedded, with upside as more partners commercialize.
- Medical School Channel as a Growth Engine: One-to-one device deployment and longitudinal tracking could create a recurring, sticky customer base.
- AI and Platform Leverage: Integration of partner AI tools into clinical workflows may drive utilization and differentiate Butterfly from hardware-only competitors.
- Home Care Execution Risk: Commercial success depends on demonstrating cost savings and patient outcomes in initial state rollouts.
- Next-Gen Launches as a Catalyst: 2027 probe and cart launches are positioned as inflection points for market share and margin expansion.
Risks
Execution on commercialization—especially in home care and next-gen probes—remains a key risk, as does the timing of partner milestones in embedded. International volatility, macro headwinds (tariffs, supply chain), and the need to balance growth investment with cash discipline could pressure near-term results. Any delays in regulatory approvals or partner commercialization could slow the flywheel effect now underway.
Forward Outlook
For Q3 2026, Butterfly guided to:
- Revenue of $26 million to $30 million (30% YoY growth at midpoint)
- Adjusted EBITDA loss of $6 million to $9 million
For full-year 2026, management raised guidance:
- Revenue of $119 million to $123 million (22% to 26% YoY growth)
- Adjusted EBITDA loss of $19 million to $23 million
Management highlighted:
- Increased investment in innovation and commercial infrastructure for both core and embedded businesses
- Embedded, home care, and AI launches as primary growth levers into 2027
Takeaways
Butterfly’s Q2 signals a platform inflection, with embedded, AI, and home care now reinforcing core device sales and setting up for multi-year compounding growth.
- Embedded Revenue Upside: Partner pipeline and milestone-driven revenue create a scalable, recurring stream that now anchors the growth narrative.
- Next-Gen and AI Ecosystem as Catalysts: 2027 launches and integrated partner AI tools could drive market share and margin expansion, but hinge on flawless execution.
- Home Care Commercialization Watch: Early outcomes and cost savings will be key to unlocking this large but unproven market segment.
Conclusion
Butterfly Network’s Q2 marks a pivotal transition from single-engine device sales to a multi-platform, software-leveraged growth story. Embedded revenue scale, AI ecosystem launches, and commercial home care set up for several potential inflection points, but sustained execution will be critical to realizing the full platform potential.
Industry Read-Through
Butterfly’s accelerating embedded and AI-driven revenue signals a broader shift in medical imaging toward platform and ecosystem business models. The move from hardware-only sales to recurring software, licensing, and per-scan fees reflects a structural change that could reshape margins and competitive dynamics across the sector. Competitors in handheld and cart-based ultrasound face pressure to match Butterfly’s integration of AI and cloud connectivity. Meanwhile, the company’s early traction in home and community care highlights the growing importance of decentralized diagnostics—a trend likely to influence payers, providers, and technology partners industry-wide. Investors should watch for similar platform flywheel effects and AI leverage in other medical device verticals.